Search alternatives:
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ng decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
e decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
301
(R)-albuterol decreases cytokine mRNA levels in activated T cells
Published 2011“…</p><p></p> (R)-albuterol, (S)-albuterol or racemic albuterol (R + S) at a dose (10M) were added to T (EL-4) cells pre-activated with mitogens Concanavalin A (Con A, 5 μg/ml) and phorbol myristate acetate (PMA, 100 ng/ml) (CP). …”
-
302
Decreased E/I synapse ratio and loss of cortico-LA synaptic plasticity in the absence of coronin 1.
Published 2014“…Scale bar, 2 microns. Data shown are mean values ± SD, <i>p</i><0.01. …”
-
303
-
304
-
305
In the absence of chloride, two-fold decrease in [Na<sup>+</sup>]<sub>e</sub> shifted GLT-1a E<sub>rev</sub> by −28 mV at both low and high glutamate concentrations.
Published 2015“…<b>(D)</b> Average E<sub>rev</sub> shifts at [Glu<sup>-</sup>]<sub>e</sub> geometric means of 37.5 and 600 μM are approximately equal when [Na<sup>+</sup>]<sub>e</sub> was decreased from 102 to 51 mM. …”
-
306
-
307
-
308
-
309
-
310
-
311
-
312
-
313
-
314
-
315
-
316
-
317
-
318
-
319
Decreased expression levels of the MYO6 protein in <i>ksv</i> mice.
Published 2017“…Expression of MYO6 is completely ablated in the hair cells of <i>Myo6</i><sup>-/-</sup> mice (C). Scale bar = 5 μm. D and E. Western blot analysis of homogenates prepared from the inner ears of +/+, +/<i>ksv</i> and <i>ksv/ksv</i> mice at P30 detected with anti-MYO6 (N-ter, D) and MYO6 (C-ter, E) antibodies (<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0183477#pone.0183477.s007" target="_blank">S2 Table</a>). …”
-
320
Baseline patient characteristics across neutralizing monoclonal antibody trials.
Published 2025Subjects: